As for the predictive nature of our “ex vivo” analysis, multiple publications have shown that the ex vivo drug response platform used in this study predicts patient response for several, although perhaps not all, targeted drugs.52,59,60 Our data indicate that MLLGA are more sensitive to chemotherapeutic drugs than an AML group that includes cases associated to high chemotherapy resistance (complex karyotype, TP53 mutations and t(6;9) rearrangements). The gene discussed is TP53; the disease is acute myeloid leukemia.